Sign in
Taking people in BangladeshNo phase

AI Model for Sorting Breast Cancer Types From Tissue Images

Studies an AI model that classifies breast cancer types from tissue slide images.

Key facts

Who runs it
Taufiq Hasan, PhD
Where
Dhaka, BangladeshSee the site
Trial code
Registry title
AI Model for Classifying Breast Cancer From Histopathology Images
Status
Recruiting
People taking part
500 people, planned
Started
11 Jan 2024
Planned end
11 Feb 2025
Type of study
Observational
Treatments tested
  • Biopsy, Mastectomy, Histopathology
Record updated
5 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women of any age who are willing to join breast cancer screening and can have a biopsy. They must have no current or past breast cancer.

Age
Any age.
Sex
Women only.
Disease stage
No current or past diagnosis of breast cancer.

Main reasons for not taking part

  • Pregnant women cannot join.
  • Severe medical conditions that make a biopsy exam inappropriate or unsafe.
  • Conditions that could interfere with the accuracy of screening results.
  • Follow-up screenings are not included.

The registry criteria, word for word

Show all 2 criteriaShow less

Other criteria

  • Inclusion criteria:; Female patients of any age can be selected as subjects; Individuals willing to participate in breast cancer screening; Availability for biopsy examination; Women with no current or prior diagnosis of breast cancer; Availability of relevant medical records for confirmation and comparison purposes
  • Exclusion criteria:; Pregnant women are excluded due to potential impacts on screening results and the necessity for special considerations during pregnancy; Individuals with severe medical conditions or circumstances that may render histopathologic examination inappropriate or unsafe are excluded; Patients with conditions that could interfere with the accuracy of screening results are excluded; Follow-up screenings are not included in this study

Where in Bangladesh

  • National Institute of Cancer Research & Hospital (NICRH)Dhaka, BangladeshContact: Farida Arjuman, FCPS, MCPSTaking people

About the trial

What the trial wants to find out

Breast cancer, a prevalent and potentially fatal disease, underscores the need for early and accurate detection to improve patient outcomes. Traditional histopathological examination, the current gold standard for diagnosis, faces limitations like subjectivity and low efficiency. In response, this research seeks to revolutionize breast cancer diagnostics by using deep learning techniques to classify invasive and noninvasive breast cancer types from histopathological images. Non-invasive cancers, like DCIS and LCIS, are confined to milk ducts or lobules, while invasive cancers spread to surrounding tissue and make up 70% of cases, often leading to poorer outcomes.

Read full original descriptionShow less

The proposed AI model aims to enhance diagnostic accuracy and efficiency, surpassing manual methods, and providing a scalable solution for diverse healthcare settings. By automating image analysis, the model seeks to democratize cancer screening, making it accessible in underserved populations and adaptable to different resources and equipment. Ultimately, this research aims to advance breast cancer detection, improve patient care, and contribute to better treatment outcomes globally.

The group in the trial

  • Women who undergo biopsy for suspected abnormal cell growth in the breast

    The cohort includes women who have undergone a biopsy due to suspected abnormal cell growth in the breast. This cohort captures a wide range of potential diagnoses, including benign conditions, noninvasive (in situ) breast cancers, and invasive breast cancers. All participants have histopathological samples collected for analysis, which serve as the basis for determining the presence and type of abnormal cell growth. The cohort will be studied using deep learning techniques to classify the biopsy samples into specific categories (normal, benign, in situ, or invasive), with the goal of improving diagnostic accuracy and efficiency in detecting breast cancer. By focusing on women undergoing biopsy, this study aims to address the diagnostic challenges faced in distinguishing between various breast tissue abnormalities, contributing to earlier detection and better clinical outcomes.

    Treatment: Biopsy, Mastectomy, Histopathology

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Study on Artificial Intelligence Algorithms for Breast Cancer Classification From Histopathology Images
Plain-language title
AI Model for Sorting Breast Cancer Types From Tissue ImagesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 December 2024